EATG » News

Conference invitation – From HIV testing and linkage to care to the integration of HIV, Hepatitis, TB & STIs

We are pleased to inform you about the European conference “from HIV testing and linkage to care to the integration of HIV, Hepatitis, TB & STIs” that will take place…

Community response to the drug-resistant TB crisis in Europe

On 12-15 May 2017, EATG, in collaboration with the Global TB Community Advisory Board (TB CAB), TBpeople (the Eastern European and Central Asian network of people with experience of TB)…

Register now! Webinar on hepatitis A in Europe

The World Health Organization reports that the recent outbreaks of hepatitis A virus (HAV) mainly affect communities of men having sex with men. We also know that people living with…

All EATG annual reports on one page

No more bulky printed booklets or large PDF files - view and read all EATG annual reports from the last four years on this page: https://www.eatgannualreport.com/ EATG has been working to…

EATG signed on TAG call for TB research for pregnant women

EATG signed a call initiated by Treatment Action Group (TAG, US) for support TB research for pregnant women that is addressed to the Task Force on Research Specific to Pregnant and…

New results from Flash! PrEP in Europe released at IAS 2017

Paris, 26 July: AIDES and PLUS announced to conference attendees from the world over results from the biggest European survey ever to be conducted regarding knowledge, interest and utilisation of…

IAS2017 – Community Paris Declaration published

At the IAS2017 Conference, Paris, 24/07/2017 It is international AIDS conferences that ignite minds and mark turning points in the fight against HIV. This is sometimes a scientific announcement (the arrival…

Lay Summaries workshop: Report now out!

Today the results from clinical trials are usually discussed within the scientific community only and are seldom spread to the general public. With the release of the EU Clinical Trials…

1st Interim Meeting for ESTICOM

EATG participated in the 1st Interim Meeting of the ESTICOM project (http://www.esticom.eu) in Brussels on 17-18/7. ESTICOM is, to some extent, the continuation and revision of the much-used and very useful…

EATG Project Management and Evaluation Webinars – All you need

EATG organised a series of webinars on the management, evaluation and monitoring of projects in advocacy. Hosted and presented by EATG member and social science researcher Ian Hodgson, the webinars…

Apply now! STEPS – Cure Workshop at the EACS Conference in Milan

If you are planning to attend the EACS meeting in Milan, Italy (October 25-27, 2017), you are invited to apply to attend the fourth community meeting on HIV cure, therapeutic…

Call for applications: European HIV Academy for Enabling Legal Environments

European HIV Academy for Enabling Legal Environments 13-14 September 2017 Venue: Deutsche AIDS Hilfe (DAH), Berlin, Germany Apply here: https://www.surveymonkey.com/r/WZRFV35 Applications will close on 26 July 2017 (23:59 CET)  …

Webinar: IP barriers to affordable quality medicines

EATG will host a community oriented webinar on intellectual property (IP) barriers to affordable quality medicines and ways in which these can be addressed on 12 July from 12:00 to…

EATG is concerned by the Cochrane review of DAA treatment against HCV infection

Direct acting agents used against hepatitis C infection are clinically effective and reliable. EATG, the pan-European network of communities of people living with and affected by hepatitis C (HCV) and…

EATG joins new coalition calling on EU to take action to eliminate viral hepatitis by 2030

Launched at an event in the European Parliament on 7 June 2017, the ACHIEVE (short for Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe) coalition calls…

EATG Tuberculosis Team met Belgian Senate

  On May 15, EATG and TBpeople, EECA network of people with tuberculosis with support from the Stop TB Partnership, convened a meeting at the Belgian Senate to raise political awareness to…

EUPATI webinar: Guidance for patient involvement in ethical review of clinical trials

EUPATI will host a webinar, Guidance for patient involvement in ethical review of clinical trials on 29 May 2017 from 17:00 to 18:30 CET. For more information about the webinar and how…

HepHIV 2017 Conference call to action and proceedings

The HepHIV 2017 Conference: HIV and Viral Hepatitis: Challenges of Timely Testing and Care was held by HIV in Europe, in collaboration with European stakeholders, from 31 January - 2…

EmERGE newsletter, May 2017

EmERGE is a project funded by the European Union’s Horizon 2020 Research and Innovation Programme. EmERGE will develop a mHealth platform to enable self-management of HIV in patients with stable disease.…

Stephan Dressler’s presentation on hepatitis B treatment

EATG held an interesting and successful ECAB meeting on viral hepatitis treatment and research in Tbilisi, Georgia in December 2016. The report on the meeting was published previously. This presentation…

Conference invitation – From HIV testing and linkage to care to the integration of HIV, Hepatitis, TB & STIs

We are pleased to inform you about the European conference “from HIV testing and linkage to care to the integration of HIV, Hepatitis, TB & STIs” that will take place…

TB CAB’s proposed development pathway for regimens to treat XDR-TB

One of the most critical scientific questions in TB today is the optimal combination of new and repurposed drugs for the treatment of extensively drug-resistant, pre- extensively drug-resistant, and hard-to-treat…

Dr. Carl June weaves together HIV and cancer research to advance cures for both

Stillbirth more frequent in women with HIV in UK and Ireland than in general population

The stillbirth rate among women living with HIV in the UK and Ireland from 2007 to 2015 was more than twice that of the general population, Graziella Favarato, presenting on…

Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV

Benefits also present for people with HIV/HCV co-infection Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish…

Evidence on second-line HIV ART regimens not yet definitive

Beyond ritonavir-boosted lopinavir plus raltegravir, the evidence base for second-line HIV/AIDS antiretroviral therapy (ART) is “thin,” necessitating more clinical trials, researchers from multiple centers and the World Health Organization say.…

Experts and patients come together on people-centred hepatitis response in the Russian Federation

Awareness is growing in the Russian Federation on the need for a strategy on viral hepatitis. Patients and doctors are pointing to the huge burden of disease and the challenges…

Community response to the drug-resistant TB crisis in Europe

On 12-15 May 2017, EATG, in collaboration with the Global TB Community Advisory Board (TB CAB), TBpeople (the Eastern European and Central Asian network of people with experience of TB)…

Terrence Higgins Trust and BHIVA advise on the use of generic HIV antiretroviral therapy

Dr Michael Brady (Terrence Higgins Trust) and Professor Chloe Orkin (British HIV Association) set out the joint position on the use of generic HIV medication. Terrence Higgins Trust and the…

Scotland may now have highest rate of drug-related deaths in the EU

Drug-related deaths in Scotland have reached the highest figure ever recorded, and the rate of such deaths may now be the highest in the EU. This highlights the urgent need…

FDA: Revisions to the GENVOYA label approved

On August 15, 2017, the FDA approved revisions to the GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) package insert to include 144 week safety, efficacy and resistance data from Studies…

Zambian President announces compulsory HIV testing

HIV Testing, Counselling and Treatment has been made compulsory in Zambia in all government-run health facilities, President Edgar Lungu announced today (August 15). He said the new policy measure is…

Communities and civil society strongly united in strategic advocacy for TB UN High Level Meeting towards ending TB

11 August 2017 - As we embark on the road to the United Nations High Level Meeting (UNHLM) on TB, the Stop TB Partnership, in collaboration with APCASO and Treatment…

Aktionsbündnis gegen AIDS warns about misleading use of data

In this German article, contributed by EATG member Peter Wiessner, Aktionsbündnis gegen AIDS warns about the misuse and misinterpretation of epidemiological and statistical data by extremists and racist authors to…

Register now! Webinar on hepatitis A in Europe

The World Health Organization reports that the recent outbreaks of hepatitis A virus (HAV) mainly affect communities of men having sex with men. We also know that people living with…

All EATG annual reports on one page

No more bulky printed booklets or large PDF files - view and read all EATG annual reports from the last four years on this page: https://www.eatgannualreport.com/ EATG has been working to…

EATG signed on TAG call for TB research for pregnant women

EATG signed a call initiated by Treatment Action Group (TAG, US) for support TB research for pregnant women that is addressed to the Task Force on Research Specific to Pregnant and…

The next AIDS pandemic

Funding cuts to key U.S. programs that support medicine and treatment are coming. And with a booming African population and drug-resistant strains on the rise, the future is grim. Read…

Centering LGBTI health and HIV at the UN’s 2017 High-Level Political Forum

This year’s United Nations High-Level Political Forum (HLPF) theme was “Eradicating poverty and promoting prosperity in a changing world” which included an in-depth review of implementation of seven Sustainable Development…

Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment

For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study –…